In Vivo Gene Editing Market to Reach USD 22.6 Billion by 2036 | Meticulous Research®

The global in vivo gene editing market was valued at USD 3.4 billion in 2025 and is projected to reach USD 22.6 billion by 2036, growing at a CAGR of 16.8% during the forecast period from 2026 to 2036. The market is gaining strong momentum as gene editing technologies move from experimental research into real clinical applications capable of treating genetic disorders with a single therapeutic intervention. In vivo gene editing allows scientists to deliver editing tools directly into the patient's body, eliminating the need for removing and modifying cells outside the body before reinfusion. This approach is opening new possibilities for treating diseases affecting organs such as the liver, heart, muscles, and central nervous system.

The growing success of CRISPR-based therapies is significantly accelerating industry expansion. One of the strongest examples comes from Intellia Therapeutics' NTLA-2001 program for transthyretin amyloidosis, which achieved a 93% reduction in serum TTR protein levels in Phase 1 trials. The therapy demonstrated that a single-dose CRISPR treatment delivered directly inside the body could generate durable gene knockdown results without requiring ex vivo manipulation. This milestone has strengthened confidence in the commercial future of in vivo editing technologies.

Download Sample Report Here : https://www.meticulousresearch.com/download-sample-report/cp_id=6671

CRISPR and LNP Technologies Driving Market Expansion

The market entered a major commercial phase after the approval of Casgevy in late 2023 by the FDA and UK MHRA. Developed by CRISPR Therapeutics and Vertex Pharmaceuticals, Casgevy became the first approved CRISPR-based medicine globally. Although the therapy uses ex vivo editing, the approval validated CRISPR as a clinically accepted technology and established a regulatory framework that now benefits in vivo gene editing developers.

Lipid nanoparticle technology has also become a major growth catalyst for the market. Initially popularized through mRNA COVID-19 vaccines, LNP delivery systems are now widely used for liver-targeted gene editing applications. Compared to viral vectors, LNPs offer better manufacturing scalability and reduced immune-related limitations. Companies including Intellia Therapeutics, Alnylam Pharmaceuticals, and Regeneron are actively investing in LNP-based delivery systems to improve targeting efficiency and allow repeat dosing opportunities.

What is Driving the Rapid Growth of the In Vivo Gene Editing Market?

The rapid growth of the in vivo gene editing market is being driven by advances in CRISPR technologies, increasing demand for curative therapies, and the development of safer delivery systems such as lipid nanoparticles. The ability to permanently correct disease-causing mutations with a single treatment has generated strong interest from patients, healthcare providers, and pharmaceutical companies. In addition, the growing number of clinical-stage programs and regulatory approvals is accelerating investment across the industry.

Prime Editing Emerging as the Next Generation Technology

Prime editing is quickly emerging as one of the most promising technologies in the in vivo gene editing landscape. Developed by David Liu and his research team, prime editing enables highly precise genetic modifications without causing double-strand DNA breaks. This technology can perform all types of base substitutions along with small insertions and deletions, making it more versatile than conventional CRISPR approaches.

Prime Medicine has already initiated early clinical development activities for prime editing therapies, while several preclinical studies have shown strong editing efficiency in liver-targeted models. The technology is particularly valuable for inherited disorders caused by single-point mutations, including metabolic and rare genetic diseases. As precision and safety continue to improve, prime editing is expected to register the fastest growth rate among all editing technologies during the forecast period.

Browse in Depth : https://www.meticulousresearch.com/product/in-vivo-gene-editing-market-6671

Cardiovascular Applications Expanding Commercial Opportunities

The application scope of in vivo gene editing is rapidly expanding beyond rare diseases into large chronic disease categories. Verve Therapeutics is leading this transition through its cardiovascular-focused base editing programs targeting the PCSK9 and ANGPTL3 genes. These therapies aim to permanently lower LDL cholesterol and triglyceride levels using a single-dose treatment approach.

Early clinical data from Verve's VERVE-101 program showed LDL cholesterol reductions ranging from 39% to 55% in treated patients. The long-term commercial opportunity in cardiovascular disease is significantly larger than rare disease applications because millions of patients globally could potentially benefit from gene editing-based preventive therapies. This shift toward broader patient populations is expected to transform the commercial dynamics of the industry over the next decade.

North America Leads While Asia-Pacific Emerges Rapidly

North America is expected to maintain the largest share of the global in vivo gene editing market in 2026 due to the strong presence of biotechnology innovators, advanced clinical research infrastructure, and supportive regulatory pathways. The United States remains the center of global gene editing development with companies such as Intellia Therapeutics, Editas Medicine, Beam Therapeutics, Prime Medicine, and Verve Therapeutics actively advancing clinical programs.

The region also benefits from high pharmaceutical R&D spending and strong academic research support from institutions including the Broad Institute, Harvard University, and UC Berkeley. Regulatory approvals for CRISPR-based therapies have further strengthened market confidence and accelerated investment activity across the sector.

Meanwhile, Asia-Pacific is expected to witness the fastest growth during the forecast period. China, Japan, South Korea, and Singapore are investing heavily in gene editing research and domestic biotechnology development. Chinese companies are actively building CRISPR and base editing pipelines, while regulatory authorities are creating structured pathways for evaluating advanced genetic therapies. Growing regional investment and improving research capabilities are positioning Asia-Pacific as an important future growth hub for in vivo gene editing technologies.

Buy the Complete Report with an Impressive Discount: https://www.meticulousresearch.com/view-pricing/1988

Competitive Landscape and Future Outlook

The competitive landscape includes a mix of specialist biotechnology firms, pharmaceutical companies, and delivery technology developers. Key players operating in the market include Intellia Therapeutics, CRISPR Therapeutics, Editas Medicine, Beam Therapeutics, Prime Medicine, Verve Therapeutics, Sangamo Therapeutics, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, Pfizer, AstraZeneca, Novartis, and Takeda Pharmaceutical.

Competition in the industry is focused on improving editing precision, delivery efficiency, manufacturing scalability, and clinical success rates. Companies that successfully develop safe delivery systems capable of targeting tissues beyond the liver are expected to gain a major competitive advantage.

As clinical programs continue advancing into Phase II and Phase III trials, the market is expected to transition from early-stage innovation toward broader commercial adoption. With increasing regulatory support, expanding therapeutic applications, and continued technological breakthroughs, the global in vivo gene editing market is positioned to become one of the most transformative sectors in modern biotechnology over the coming decade.

Related Reports:

AI in Endoscopy Market: https://www.meticulousresearch.com/product/ai-in-endoscopy-market-6621
In Vitro Diagnostics (IVD) Market: https://www.meticulousresearch.com/product/ivd-market-4858
5G in Healthcare Market: https://www.meticulousresearch.com/product/5g-in-healthcare-market-5431

About Us:

We are a trusted research partner for leading businesses worldwide, empowering Fortune 500 organizations and emerging enterprises with actionable market intelligence tailored to drive revenue transformation and strategic growth. Our insights reveal forward-looking revenue opportunities, providing our clients with a competitive edge through a diverse suite of research solutions-syndicated reports, custom research, and direct analyst engagement.

Each year, we conduct over 300 syndicated studies and manage 60+ consulting engagements across eight key industry sectors and 20+ geographic markets. With a focus on solving the complex challenges facing global business leaders, our research enables informed decision-making that propels sustainable growth and operational excellence. We are dedicated to delivering high-impact solutions that transform business performance and fuel innovation in the competitive global marketplace.

Contact Us:

Meticulous Market Research Pvt. Ltd.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
Email- sales@meticulousresearch.com
USA: +1-646-781-8004
Europe: +44-203-868-8738
APAC: +91 744-7780008
Visit Our Website: https://www.meticulousresearch.com/
For Latest Update Follow Us:
LinkedIn- https://www.linkedin.com/company/meticulous-research

This release was published on openPR.